tbuckley/cabot-search huggingface dataset:
Abstract 15764: Aortic Valve Intervention for Severe Aortic Stenosis Improves Outcomes Following Non-cardiac Surgery
Authors: Sushil A Luis, Sorin V Pislaru, Christopher G Scott, Garvan C Kane, Martin D Abel, Vuyisile T Nkomo, Patricia A Pellikka
Journal: Circulation (2015)

Background: Non-cardiac surgery (NCS) in patients with severe aortic stenosis has traditionally been associated with high perioperative mortality. Aortic valve replacement is recommended prior to elective NCS, but the impact of this strategy has not been systematically assessed. Methods: A retrospective review was performed of all patients with severe aortic stenosis undergoing major NCS at Mayo Clinic between 2000 and 2013. Patients undergoing aortic valve intervention (AVI) prior to NCS were compared to those undergoing surgery without prior AVI (control). Patients undergoing emergency surgery were excluded. Primary endpoint was occurrence of major adverse cardiac events (MACE; combination of death, stroke, myocardial infarction, new/worsening heart failure, ventricular arrhythmia) within 30 days of NCS; secondary endpoints were mortality at 30 days and 1 year after NCS. Results: 180 patients (age 74.5 ± 10.5 years, 64% male) who underwent NCS within 12 months after AVI, were compared to 232 patients (age 76.6 ± 10.7 years, 56% male) in the control group. Patients undergoing AVI were more often symptomatic than controls (41% vs 26%, p = 0.002). MACE was significantly higher in the control group (21.6% vs 5.6%, p &lt; 0.001), mainly due to the increased risk of heart failure in the postoperative period in this group (18.5% vs 2.2%, p &lt; 0.001). There was no significant difference in the rate of myocardial infarction (1.7% vs 0.6%, p = 0.39), ventricular arrhythmia (0.9 % vs 0 %, p = 0.51) or stroke (0.9 % vs 0 %, p = 0.51). Kaplan-Meier assessment demonstrated no significant difference at 30 days but a reduction in 1 year mortality in the AVI group compared to the control group (Figure). Conclusions: Pre-operative AVI for severe aortic stenosis results in reduced heart failure and improved 1 year survival. However, other MACE and 30 day mortality appears unchanged. Pre-operative AVI should be considered in symptomatic patients, where the benefit of AVI is demonstrated to be greatest.
P102 The utility of radioisotope bone scans in the liver transplant assessment for hepatocellular carcinoma
Authors: K Sheikh, V Warbey, J O'Beirne, A Burroughs, D Patch, D Thorburn
Journal: Gut (2010)

Introduction  The incidence of skeletal metastases from hepatocellular carcinoma (HCC) is estimated to be 2–16%. It is well established that radioisotope bone scans can detect cancer earlier than cross sectional imaging. The role of bone scans in pre-transplant assessment has been discussed in the literature but its place in the assessment algorithm is not clearly established.  Aim  The aim of this study is to determine the utility of radioisotope bone scans in patients with a diagnosis of HCC undergoing transplant pre-assessment.  Method  Radioisotope bone scan results were reviewed for all patients undergoing liver transplant assessment for HCC at our unit from 1989 to 2009. Patients were initially selected for transplant assessment based on favourable HCC staging on cross sectional imaging. Patients undergoing bone scan had the result reviewed retrospectively as normal or abnormal. All abnormal scans we then reassessed against all available imaging and classified as showing benign or malignant changes. Patient outcomes were considered in relation to bone scan results.  Results  During this period 216 patients with a primary or secondary diagnosis of HCC were assessed for liver transplantation. Two hundred and three patients were listed for transplant and 148 were eventually transplanted. The results of their bone scans are as below (Abstract P102 Table 1).  Amongst patients listed for transplant, 22 (11%) cases had abnormal bone scans with 12 cases in transplanted group showing false positive results for reasons including degenerative changes, healing traumatic fractures and tracer uptake in gynaecomastia. One patient had a scan with high suspicion for bony secondaries. This patient initially listed for transplant was removed from the list due to active substance misuse, and subsequently became too ill before bony abnormalities could be confirmed. The recurrence rates of HCC were 12.5 % in transplanted patients who underwent bone scans and 9% in those transplanted without a bone scan.  Conclusion  Bone scans were not performed as rigorously as expected with 40% of listed patients with no prior radioisotope imaging. However there were no significant differences in recurrence rates in those that did and did not have bones scans. In a population of patients assessed for liver transplant with cross sectional imaging indicating HCC to be within transplant criteria bone scans had a false positive rate of 18% (24/131). The result of bone scanning did not influence the decision to list with only 1 patient exhibiting feature of bony metastases. This patient was subsequently removed from the list for other reasons.
Bluish discoloration of the esophagus: cavernous hemangioma of the pharynx and larynx with esophageal involvement
Authors: Eduardo Rodrigues-Pinto, Pedro Pereira, Guilherme Macedo
Journal: Endoscopy (2015)

An 18-year-old man was referred for upper gastrointestinal endoscopy to evaluate presurgically a cavernous hemangioma of the pharynx and larynx. This condition, which caused him to experience laryngeal stridor, had been diagnosed when he was 16 years old. Therapy with propranolol, carbon laser surgery, and intralesional injection of dexamethasone had not reduced the size of the hemangioma.
EPN-10UPDATING THE PROGNOSTIC IMPORTANCE OF RESECTION STATUS AND CHROMOSOME 1q GAIN IN CHILDREN TREATED ACCORDING TO THE FIRST SIOP 1999-04 TRIAL FOR PAEDIATRIC INTRACRANIAL EPENDYMOMA
Authors: John-Paul Kilday, Rebecca J. Chapman, Lisa C.D. Storer, James Lowe, Thomas S. Jacques, Tim Jaspan, Donald MacArthur, Conor Mallucci, Nicky Thorp, Maura Massimino, Eric Bouffet, David Ellison, David Machin, Richard G. Grundy
Journal: Neuro-Oncology (2016)
Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection
Authors: L. James Lee, Zhaogang Yang, Mohammad Rahman, Junyu Ma, Kwang Joo Kwak, Joseph McElroy, Konstantin Shilo, Chandra Goparaju, Lianbo Yu, William Rom, Taek-Kyun Kim, Xiaogang Wu, Yuqing He, Kai Wang, Harvey I. Pass, S. Patrick Nana-Sinkam
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Estrogen-Induced Tumors of the Kidney. I. Incidence of Renal Tumors in Intact and Gonadectomized Male Golden Hamsters Treated With Diethylstilbestrol<xref ref-type="fn" rid="fn1"><sup>2</sup></xref><xref ref-type="fn" rid="fn2"><sup>3</sup></xref>
Authors: Hadley Kirkman, R. L. Bacon
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Estrogen-Induced Tumors of the Kidney. I. Incidence of Renal Tumors in Intact and Gonadectomized Male Golden Hamsters Treated With Diethylstilbestrol Get access Hadley Kirkman, Hadley Kirkman Search for other works by this author on: Oxford Academic PubMed Google Scholar R. L. Bacon R. L. Bacon Department of Anatomy, Stanford University School of Medicine, Stanford, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 745–755, https://doi.org/10.1093/jnci/13.3.745 Published: 01 December 1952 Article history Received: 08 September 1952 Published: 01 December 1952
HG-08ONCOLYTIC HERPES SIMPLEX VIRUS: AN ANTI-INVASIVE THERAPEUTIC STRATEGY FOR PAEDIATRIC HIGH GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: Julia Cockle, Elizabeth Ilett, Anke Brüning-Richardson, Jill Thompson, Tim Kottke, Karen Scott, Ewan Morrison, Azam Ismail, Ailsa Rose, Susan Picton, Richard Vile, Peter Selby, Susan Short, Alan Melcher
Journal: Neuro-Oncology (2016)
Ongoing outbreak of mumps infection in Oban, Scotland, November 2010 to January 2011
Authors: J Walker, S Huc, K Sinka, A Tissington, K Oates
Journal: Eurosurveillance (2011)

We report on an ongoing outbreak of 119 cases of mumps virus infection in the Oban area of Scotland,from 29 November 2010 to 31 January 2011. The median age of cases was 20 years, with the highest incidence in the 13-19-year-olds. A total of 53 cases had received two doses of measles-mumps-rubella (MMR) vaccine,in accordance with the United Kingdom vaccination schedule, while 33 had received only one dose and 30 had not been vaccinated.
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Authors: Kevin E. Chan, Robert P. Giugliano, Manesh R. Patel, Stuart Abramson, Meg Jardine, Sophia Zhao, Vlado Perkovic, Franklin W. Maddux, Jonathan P. Piccini
Journal: Journal of the American College of Cardiology (2016)
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP)
Authors: Elizabeth S. Robinson, Aimee S. Payne, Lisa Pappas-Taffer, Rui Feng, Victoria P. Werth
Journal: Journal of the American Academy of Dermatology (2016)
Abstract LB-138: Use of cerebral organoids to model pediatric gliomas with H3.3K27M and H3.3G34R
Authors: Amin Ismail
Journal: Cancer Research (2015)

Abstract Glioblastoma (GBM) is the most devastating brain cancer with dismal prognosis both in adults and children and accounts for 16% of primary brain tumors. Despite aggressive therapeutic approaches, the majority of patients die within one year after diagnosis. Giving the limitation of current GBM mouse models, which do not reflect the biological properties of human tumors, in particular, tumor heterogeneity and pathogenesis, there is a growing need for new models. Current in vitro 3D models involve the use of hydrogel scaffolds and cell lines, which do not represent a viable developmental context where the tumor mass interacts with and invades the surrounding brain tissues. Starting with pluripotent human embryonic stem cells we reproduced a 3D tissue structure (so-called cerebral organoid) representing a developing human brain in vitro. We engineered these mini-brains to express oncogenic hits responsible for the derivation of tumors in pediatric GBM patients. Pediatric GBM is driven by a combination of epigenetic and genetic hits including the expression of a mutant histone H3 variant H3F3A (mutated at K27M or G34R) or a gain of function mutant isocitrate dehydrogenase IDH1R132H in combination with the loss of the histone remodeling factor ATRX and/or p53 tumor suppressor. We used a combination of these oncogenic hits to create a model of tumor engineering representing the first 3D human tissue model of GBM. This model combines the accurate multi-lineage differentiation and physiology of human brain with the easiness of manipulation of in vitro systems. H&amp;E staining of the modified organoids shows remarkable dysplasia reminiscent of human primary glioma. Different genetic hits result in different type of dysplasia with IDH1R132H showing distinct morphology, suggestive of a broad range of applicability to model oncogenic-dependence in pediatric GBM. Cerebral organoids may also be used as a model to study tumor invasion starting with glioma stem-like cells (GSCs, which are believed to be the tumor-initiating cells in GBM). Indeed 923 GSCs (which are not invasive in mice brain) quickly and spontaneously (within few days) invade a co-cultured cerebral organoid. This study is the first to engineer a human CNS tumor in vitro. The model carries a tremendous potential to uncover the pathogenesis and initiation of brain cancer in pediatric settings. Citation Format: Amin Ismail. Use of cerebral organoids to model pediatric gliomas with H3.3K27M and H3.3G34R. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-138. doi:10.1158/1538-7445.AM2015-LB-138
Colorectal Cancer Screening
Authors: John M. Inadomi
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
Authors: Z A Hing, H Y J Fung, P Ranganathan, S Mitchell, D El-Gamal, J A Woyach, K Williams, V M Goettl, J Smith, X Yu, X Meng, Q Sun, T Cagatay, A M Lehman, D M Lucas, E Baloglu, S Shacham, M G Kauffman, J C Byrd, Y M Chook, R Garzon, R Lapalombella
Journal: Leukemia (2016)
Editors to Readers
Authors: J. R. E.
Journal: Annals of Internal Medicine (1969)

Editorials1 January 1969Editors to ReadersJ. R. E., E. J. H.J. R. E.Search for more papers by this author, E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-70-1-219 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAs the new year begins, the editors wish to share again with our readers some thoughts and comments about this, our venture in common, the ANNALS. Such a journal as oursisa venture to which many people contribute: the authors who are the prime source of the journal's intellectual sustenance; the readers whose continuing education as physicians is the main objective of the venture; and in between these two groups—the editorial staff, the business office, the printers, the Editorial Board, the many manuscript reviewers, and the editors. In presiding over the stirring of this medical journalistic brew, your editors... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1969Volume 70, Issue 1Page: 219-220KeywordsContinuing medical education ePublished: 1 December 2008 Issue Published: 1 January 1969 PDF downloadLoading ...
EPN-11PROGNOSTIC RELEVANCE OF TP53INP1 IN PEDIATRIC EPENDYMOMA
Authors: Yulia Margolin Miller, Natalia Yanichkin, Keren Shichrur, Helen Toledano, Shalom Michoviz, Meora Feinmesser, Suzana Fichman-Horn, Isaac Yaniv, Smadar Avigad
Journal: Neuro-Oncology (2016)
Postinfectious encephalitis: a coregistered SPECT and magnetic resonance imaging study.
Authors: EMMANUEL ITTI, KENNETH HUFF, MARCIA CORNFORD, LAURENT ITTI, KALYAN PORURI, FRED MISHKIN
Journal: Clinical Nuclear Medicine (2002)

EMMANUEL, ITTI M.D.*; KENNETH, HUFF M.D.†; MARCIA, CORNFORD E. M.D.‡; LAURENT, ITTI P h.D.§; KALYAN, PORURI M.D.*; FRED, MISHKIN S. M.D.* Author Information
ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG)
Authors: Mary L. Affronti, Henry S. Friedman, Annick Desjardins, Gordana Vlahovic, Dina M. Randazzo, James E. Herndon, Frances McSherry, Eric S. Lipp, Alex Mannerico, Woody Massey, Elizabeth Miller, Deborah Iden, Katherine B. Peters
Journal: Neuro-Oncology (2015)

BACKGROUND: Prognosis of recurrent MG remains poor with a median survival of 3-11 months for patients on BEV-containing regimens. Few active evidence-based treatments are available & response rates have been <20% with a 6-month progression-free survival (PFS-6) of <9-15% for salvage therapy prior to treatment with BEV. BEV, an antibody to VEGF, is an active agent for recurrent MG with a PFS-6 of ∼40% & overall response rate of ∼21.2%. Rilotumumab is a human monoclonal antibody that blocks human hepatocyte growth factor (HGF) & its receptor c-Met. HGF/c-Met signaling plays a role in MG tumorgenicity inducing angiogenesis & expression of additional angiogenic autocrine factors such as VEGF. Combination of rilotumumab (c-Met inhibitor) with BEV to block vascular invasion & tumor proliferation may demonstrate synergistic tumor growth inhibition. METHODS: Subjects with recurrent BEV-naive MGs received rilotumumab at 20 mg/kg combined with BEV at 10 mg/kg every two weeks. MRI's were obtained after each 6-week cycle. Primary outcome, overall best response, was assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Secondary endpoints were PFS, overall survival (OS) & toxicity. RESULTS: 36 patients were accrued. 22(61%) were male, 75% were ≥50 years, 25% had ≥2 prior progressions. Objective response rate was 27.8% (95%CI: 15.7%,44.1%). Median follow-up on patients was 38.5 months. Median OS was 10.3 months (95%CI 7,16.6), & 6-month OS was 72.2% (95%CI: 54.5%,84%). Median PFS was 4.8 months (95%CI: 2.7,7.1), & PFS-6 was 41.7% (95%CI: 25.6%,57.0%). Treatment-related grade ≤2 events included weight gain, fatigue, allergic rhinitis, and voice alteration; grade ≥3 events involved 4(11%) patients with thrombolytic events including one patient death from pulmonary embolism. CONCLUSIONS: While rilotumumab in combination with BEV did not significantly improve objective response compared to BEV alone, consideration of the c-Met pathway for targeted therapy could be considered for further investigation.
HG-128BO25041 - A PHASE II OPEN-LABEL, RANDOMIZED, MULTI CENTRE COMPARATIVE STUDY OF BEVACIZUMAB BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIGH GRADE GLIOMA
Authors: Jacques Grill, Darren Hargrave, Maura Massimino, Eric Bouffet, Amedeo Azizi, Geoffrey McCowage, Adela Cañete, Frank Saran, Marie-Cecile Le Deley, Pascale Varlet, Paul Morgan, Tim Jaspan, Chris Jones, Helen Smith, Josep Garcia, Magalie Hilton, Lauren Abrey, Raphael Rousseau, Gilles Vassal
Journal: Neuro-Oncology (2016)
Mitral valve prolapse. An update
Authors: R M Jeresaty
Journal: JAMA (1985)

MITRAL valve prolapse (MVP), defined as echocardiographic, angiographic, and pathological protrusion of the mitral leaflets into the left atrium during systole, may affect about 5% of the population and was first widely recognized in the mid-1960s.<sup>1-3</sup>It is frequently associated with a click and/or murmur. A syndrome consisting of nonspecific symptoms, electrocardiographic abnormalities, and arrhythmias has been recognized by many investigators.<sup>1-3</sup>Although doubt has recently been expressed about the existence of this syndrome,<sup>4-6</sup>the complications of MVP,<sup>2,7-10</sup>albeit rare, earn for it an important place in modern cardiology and may represent its "raison d'être." <h3>Pathology and Etiology</h3> Because of the generally benign course of MVP, its underlying pathology has been well documented only in advanced forms that are associated with severe mitral insufficiency and have been termed the "floppy mitral valve."<sup>7,8</sup>Of great interest has been the demonstration of similar pathological changes in 26 patients
Synergism between serum factor(s) and erythropoietin in inducing murine megakaryocyte colony formation: the synergistic factor in serum is distinct from interleukin-11 and stem cell factor (c-kit ligand) [letter]
Authors: J Tsukada, M Misago, R Ogawa, S Oda, I Morimoto, S Eto, M Kikuchi
Journal: Blood (1993)
Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC).
Authors: D. Ross Camidge, Sai-Hong Ignatius Ou, Geoffrey Shapiro, Gregory Alan Otterson, Liza Cosca Villaruz, Miguel Angel Villalona-Calero, A. John Iafrate, Marileila Varella-Garcia, Sanja Dacic, Stephanie Cardarella, Weiqiang Zhao, Lesley Tye, Patricia Stephenson, Keith D. Wilner, Leonard Philip James, Mark A. Socinski
Journal: Journal of Clinical Oncology (2014)

8001 Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the treatment of advanced ALK-positive NSCLC. Efficacy and safety data are presented for crizotinib in patients with advanced c-Met-amplified NSCLC within 3 categories of amplification MET/CEP7 ratio ≥1.8-≤2.2 (Low), >2.2-<5 (Intermediate) and ≥5 (High). Methods: c-METamplification status was determined by FISH, with 10-12 patients to be enrolled into each amplification category. If 2 or more objective responses occur in a category, 19 additional patients are to be enrolled. This study is part of an ongoing phase 1 crizotinib study (NCT00585195). Patients received crizotinib 250 mg BID. Responses were assessed using RECIST v1.0. Results: At data cut-off, 16 patients were enrolled; 3 were subsequently determined not to have an amplification meeting MET/CEP7 criteria. 13 patients with c-MET-amplified NSCLC [Low (n=1), Intermediate (n=6) and High (n=6)] enrolled and received crizotinib, with 12 evaluable for response. Median age was 63 years (range 42-79), 92% of patients were ECOG 0 or 1 and 77% were ex-smokers. To date 4 PRs (33%; 95% CI: 10,65) have been observed (Low (n=0), Intermediate (n=1; 20%) and High (3; 50%). Median duration of response was 35 weeks [95% CI: 16,112]. Median treatment duration was 15.7 weeks (range 4 -188), and 6 patients were on treatment at the data cut-off; 5 patients have died (all disease-related). 75% of the 16 patients enrolled had treatment-related adverse events (AEs): most commonly diarrhea (50%), nausea (31%), vomiting (31%), peripheral edema (n=25%) and visual impairment (25%). Most AEs were grade 1 in severity. There were no treatment-related serious AEs or treatment-related permanent discontinuations. Accrual of patients with c-Met-amplified NSCLC is ongoing. Conclusions: Crizotinib appears to have antitumor activity in patients with c-Met-amplified NSCLC and a generally tolerable and manageable AE profile. These findings warrant further study of crizotinib in advanced c-MET-amplified NSCLC and ongoing exploration of the MET/CEP7 ratio associated with clinical benefit. Clinical trial information: NCT00585195.
Protease Inhibitors as Anticarcinogens&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Walter Troll, Ph.D., Krystyna Frenkel, Ph.D., Rakoma Wiesner, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1984)

editorials as a means of transmitting to investigators in cancer
Response to Letter Regarding Article, “MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis”
Authors: Varun Nagpal, Rahul Rai, Aaron T. Place, Sheila B Murphy, Suresh K. Verma, Asish K. Ghosh, Douglas E. Vaughan
Journal: Circulation (2016)
HG-86IMMUNOTHERAPY OF WILMS TUMOR 1 PEPTIDE VACCINATION AGAINST RECURRENT GLIOBLASTOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA IN CHILDREN
Authors: Naoki Kagawa, Yoshiko Hashii, Ryuichi Hirayama, Yasuyoshi Chiba, Takako Miyamura, Hideyuki Arita, Yasunori Fujimoto, Naoya Hashimoto, Haruo Sugiyama, Toshiki Yoshimine
Journal: Neuro-Oncology (2016)

We have ever proven safety and effectiveness of Wilms tumor 1 peptide (WT1) vaccination for newly-diagnosed or recurrent Overall survival